Celgene's Patient Support Coordinators assist patients and healthcare providers to navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Revlimid.
Celgene has developed a new program called Fast Track for First Prescription™ to help eligible patients receive their first prescriptions for a Celgene product quickly and efficiently.
Celgene's Patient Support Coordinators assist patients and healthcare providers to navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Revlimid.
Using thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades. This provides a basic understanding of thalidomide therapy.
We asked the experts about thalidomide alone and in trials with various other agents--response, side effects, and the impact of FDA approval on its use in myeloma. Our "Ask the Expert" Videos are a new feature of our expanded website.
Breakthroughs in the treatment of blood cancer were presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta. In one of the findings, Thalomid®, when used in the treatment of newly diagnosed elderly patients with the disease, was found to be more effective than stem cell transplants. This once dangerous drug is now bringing new hope to a new generation of patients. Video featuring patients Hardy Jones and Paul Nicholss and the IMF's Dr. Brian Durie.
Thalidomide has been used since 1997 in the treatment of myeloma. Remarkable efficacy has been observed both alone and in combination with dexamethasone and other drugs. Strangely, only recently have comparative trials been completed to show the clear added benefit of thalidomide and the drug still awaits formal FDA approval for myeloma treatment. Two recent studies have lead to some confusion about thalidomide efficacy.
back
print
related articles
